Exploiting inflammation for therapeutic gain in pancreatic cancer

Steele, C.W., Jamieson, N.B. , Evans, T.R.J. , McKay, C.J., Sansom, O.J. , Morton, J. and Carter, C.R. (2013) Exploiting inflammation for therapeutic gain in pancreatic cancer. British Journal of Cancer, 108(5), pp. 997-1003. (doi: 10.1038/bjc.2013.24)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy associated with <5% 5-year survival, in which standard chemotherapeutics have limited benefit. The disease is associated with significant intra- and peritumoral inflammation and failure of protective immunosurveillance. Indeed, inflammatory signals are implicated in both tumour initiation and tumour progression. The major pathways regulating PDAC-associated inflammation are now being explored. Activation of leukocytes, and upregulation of cytokine and chemokine signalling pathways, both have been shown to modulate PDAC progression. Therefore, targeting inflammatory pathways may be of benefit as part of a multi-target approach to PDAC therapy. This review explores the pathways known to modulate inflammation at different stages of tumour development, drawing conclusions on their potential as therapeutic targets in PDAC.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Jamieson, Professor Nigel and Carter, Mr Ross and Steele, Dr Colin and Evans, Professor Jeff and Morton, Professor Jen and Sansom, Professor Owen
• Authors: Steele, C.W., Jamieson, N.B., Evans, T.R.J., McKay, C.J., Sansom, O.J., Morton, J., and Carter, C.R.
• College/School: College of Medical Veterinary and Life Sciences > School of Cancer Sciences
• Journal Name: British Journal of Cancer
• Publisher: Nature Publishing Group
• ISSN: 0007-0920
• ISSN (Online): 1532-1827
• Published Online: 05 February 2013
• Copyright Holders: Copyright © 2013 Cancer Research UK
• First Published: First published in British Journal of Cancer 108(5):997-1003
• Publisher Policy: Reproduced under a Creative Commons License